About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly

News

Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release, IR) and Seroquel XR® (extended release formulation) in the local markets

September 11,2020

Luye Pharma’s New Alzheimer’s Drug LY03013 Starts Clinical Trials in China

Luye Pharma Group announced today that the company has received the approval from the Center for Drug Evaluation of China to begin clinical trials for the new drug product Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD, LY03013). The product was developed for the treatment of Alzheimer's disease by Luye Pharma AG, the company’s German subsidiary, on its proprietary transdermal patch platform. Marketing Authorization applications for Rivastigmine MD have been formally accepted and are under review by the relevant authorities in seven European countries: Germany, the United Kingdom, Spain, Italy, Portugal, Luxembourg and Greece.

September 01,2020

Read More

Luye Pharma Starts Clinical Trials for Licensed Innovative Drug Lurbinectedin in ...

Luye Pharma Group announced today that the clinical trials application for Lurbinectedin, an innovative anticancer drug licensed-in from Pharma Mar, S.A. (PharmaMar), has been approved by the Center for Drug Evaluation of China, for the treatment of Small Cell Lung Cancer (SCLC). Lurbinectedin is an inhibitor of RNA polymerase II and a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, Lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. The drug was approved according to the U.S. Food and Drug Administration’s (FDA) “Accelerated Approval” process in June (Brand Name: Zepzelca™), for the treatment of adult patients with metastatic SCLC with disease progression, after platinum-based chemotherapy.

September 01,2020

Luye Pharma’s Licensed Drug Lurbinectedin Included in NCCN Guidelines in the ...

Luye Pharma Group’s partner PharmaMar announced that its innovative anticancer drug, Lurbinectedin, has been added to the National Comprehensive Cancer Network’s (NCCN®) Clinical Practice Guidelines in Oncology for the treatment of Small Cell Lung Cancer (SCLC).

July 15,2020

Clinical Trials for Luye Pharma’s Licensed Drug Lurbinectedin to Begin in China ...

Luye Pharma Group has announced that the clinical trials application for Lurbinectedin, an innovative anticancer drug licensed-in from PharmaMar, has been accepted by the Center for Drug Evaluation of China, for the treatment of Small Cell Lung Cancer.

June 29,2020

Investors

August 26,2020

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR CLINICAL TRIAL FOR LURBINECTEDIN (LY01017) IN CHINA

Stock Code:02186.HK

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company

Adequate Career Opportunities for Female Professionals Sammy Jiang VP of Strategy & Business Development, Luye Pharma
Learn the Best of the People around You Yan Yameng HR BP, Luye Pharma
Luye Pharma Is like an International Family Tim Maguire Business Development Director of US
R&D Center, Luye Pharma
What I think When I Run Andy Siow APAC Commercial Director, Luye Pharma (International)
To Learn and Grow through Problem Discovery and Resolution Yu Fei Director of Analytical Research and Development, R&D Center, Luye Pharma
To Practice with Every Opportunity Wang Chao Director of Engineering Department II, Shandong Luye
My Three Years with Luye US Antonia Sacchetti Office Manager, Luye Pharma (US)
Run, CMO Guy Ma Lewei CMO Project Manager, Luye Pharma
Attracted by Luye's Development Strategy and Innovation Mechanism Dr. Wang Guangquan VP of Biologics technology Transfer and Commercial Manufacturing (including CMO), Luye Pharma
Unveiling the Legend of Innovation: The Perseverance of Our R&D Staff Xue Peng Formulation Scientist,Luye Pharma
Adequate Career Opportunities for Female Professionals Sammy Jiang VP of Strategy & Business Development, Luye Pharma
Learn the Best of the People around You Yan Yameng HR BP, Luye Pharma
Luye Pharma Is like an International Family Tim Maguire Business Development Director of US
R&D Center, Luye Pharma
What I think When I Run Andy Siow APAC Commercial Director, Luye Pharma (International)
To Learn and Grow through Problem Discovery and Resolution Yu Fei Director of Analytical Research and Development, R&D Center, Luye Pharma
To Practice with Every Opportunity Wang Chao Director of Engineering Department II, Shandong Luye
My Three Years with Luye US Antonia Sacchetti Office Manager, Luye Pharma (US)
Run, CMO Guy Ma Lewei CMO Project Manager, Luye Pharma
Attracted by Luye's Development Strategy and Innovation Mechanism Dr. Wang Guangquan VP of Biologics technology Transfer and Commercial Manufacturing (including CMO), Luye Pharma
Unveiling the Legend of Innovation: The Perseverance of Our R&D Staff Xue Peng Formulation Scientist,Luye Pharma